glaucoma

(redirected from primary open-angle glaucoma)
Also found in: Dictionary, Medical, Encyclopedia.
Related to primary open-angle glaucoma: Normal Tension Glaucoma, glaucoma simplex
Graphic Thesaurus  🔍
Display ON
Animation ON
Legend
Synonym
Antonym
Related
  • noun

Words related to glaucoma

an eye disease that damages the optic nerve and impairs vision (sometimes progressing to blindness)

References in periodicals archive ?
This lecture will, in relation to primary open-angle glaucoma (POAG), review the statistical procedures for identifying visual field abnormality and discuss the graphical and statistical techniques for illustrating, and defining abnormality, of the retinal nerve fibre layer (RNFL) and of the macular ganglion cell inner plexiform layer thicknesses imaged by optical coherence tomography.
Despite favourable results, laser therapy has not replaced medications as primary therapy in patients with primary open-angle glaucoma (POAG).
Statistically, people with primary open-angle glaucoma are deficient in omega-3 fatty acids (Ren et al.
There are several types of glaucoma, but the most common ones are primary open-angle glaucoma, or POAG, and normal tension glaucoma, also known as low-tension glaucoma.
The Rogers family suffers from a rare subtype of primary open-angle glaucoma.
In a Phase 2, randomized, double-masked, placebo-controlled, dose-ranging study, trabodenoson was delivered as an eye-drop formulation in 144 patients with primary open-angle glaucoma.
This book aims to provide the background knowledge required by optometrists who are either interested in or taking part in co-management/shared-care schemes in primary open-angle glaucoma.
During a follow-up screening of these patients at Hopkins, ophthalmologists diagnosed the optic-nerve damage that characterizes primary open-angle glaucoma in 100 blacks and 32 whites.
a leader in the development of innovative drug candidates to address significant diseases of the eye, today announced that a multi-center, randomized, double-masked, placebo-controlled, dose-ranging Phase 2 clinical trial to evaluate the efficacy and safety of its novel eye-drop trabodenoson, also known as INO-8875, in patients with primary open-angle glaucoma or ocular hypertension successfully achieved its primary and secondary endpoints.
They included: Floppy eyelid syndrome (this disorder causes eyelids to evert spontaneously during sleep, resulting in excessive watering, stickiness, discomfort and blurred vision); glaucoma (OSA is linked to two forms of this disease, primary open-angle glaucoma and normal-tension glaucoma); Nonarteritic anterior ischemic optic neuropathy (characterised by the sudden painless onset of vision loss in one eye, when waking) and papilledema.
The European Glaucoma Society (EGS) guidelines outline that bimatoprost appears to be one of the effective, well-tolerated agents for the reduction of IOP in patients with primary open-angle glaucoma and ocular hypertension.
a leader in the development of innovative drug candidates to address significant diseases of the eye, today announced that final data from a Phase 2 clinical trial of trabodenoson, also known as INO-8875, in patients with primary open-angle glaucoma or ocular hypertension will be presented at the Ophthalmology Innovation Summit on Thursday, November 8, 2012 at the Chicago Marriott Downtown Magnificent Mile in Chicago, IL.
Clinicians know that increased IOP contributes to glaucoma progression in a majority of patients with primary open-angle glaucoma.
New data confirm a five-year risk assessment tool will help ophthalmologists better predict which patients have an increased risk of developing glaucoma - Analysis finds that patients with elevated intraocular pressure (IOP) - along with other predictive risk factors, such older age (40+) - are at highest risk of progressing to primary open-angle glaucoma (POAG) - Investigator: 'It is critical to continue to evaluate and refine innovative, predictive models in ophthalmic medicine in order to provide the best treatment possible for patients.